Celebrex Lawsuit |
|
Canada Lawyers Represent Canadians Injured by Celebrex |
|
Celebrex is a popular arthritis drug belonging to the COX-2 family of pharmaceuticals. A recent clinical study indicated that Celebrex may be linked to higher incidences of life-threatening cardiovascular problems, including heart attack and stroke. A competing drug, Vioxx, already has been withdrawn from the market after numerous clinical studies found similar problems. |
|
Celebrex Side Effects |
|
 |
In the study conducted by the National Cancer Institute, patients taking Celebrex suffered more than twice as many heart attacks and strokes as those taking a placebo. Those taking a 400mg daily dosage had a 2.5 times greater risk. Patients taking 800mg were 3.4 times more likely to suffer a serious cardiovascular problem. |
Celebrex Recall |
|
|
In spite of strong evidence that Celebrex may be linked to life-threatening problems, Pfizer announced they would not recall the drug. The company contends that the results of this study are not consistent with earlier clinical studies and therefore a recall is not necessary. Merck, the manufacturer of Vioxx, came under heated criticism for failing to withdraw the drug after becoming aware of serious problems. Merck also disregarded and discredited clinical studies that indicated an elevated risk of heart attack and stroke. |
Celebrex Lawyers Canada |
|
 |
Greg Monforton and Partners is handling legal claims against Pfizer on behalf of Canadians injured by the arthritis drug Celebrex. We people who suffered heart attacks, blood clots and strokes after using Celebrex. If you or a loved one has been injured as a result of Celebrex, we encourage you to contact us. We are representing clients throughout Canada in lawsuits against Pfizer. For free answers to your questions about the Celebrex lawsuit, please complete our online form. |
|
|
Current Consumer Cases |
Contact Us |
Health Canada Investigating Celebrex |
A spokesperson for Health Canada said the agency is pressing Pfizer for more information about the results of the clinical study. The agency encourages patients taking Celebrex to discuss any concerns with their physician. The agency did not comment on whether they expect to force a Celebrex recall. |